Scientists get first-ever glimpse of 'teenage' HIV-neutralizing antibody
Scientists have described the first-ever immature or 'teenage' antibody found in a powerful class of immune molecules effective against HIV. The new knowledge of the evolution and key traits of anti-HIV antibodies could help researchers design a vaccine to prevent AIDS, they say. Ref. Source 3n.
The CRISPR/Cas9 gene-editing platform may need more tweaking before it can be used as an effective antiviral, reports a new study. Researchers who used CRISPR/Cas9 to mutate HIV-1 within cellular DNA found that while single mutations can inhibit viral replication, some also led to unexpected resistance. The researchers believe targeting multiple viral DNA regions may be necessary for the potential antiviral aspect of CRISPR/Cas9 to be effective. Ref. Source 1s.
Scientists jump hurdle in HIV vaccine design. Scientists have made another important advance in HIV vaccine design. The development was possible thanks to previous studies showing the structures of a protein on HIV’s surface, called the envelope glycoprotein. The scientists used these structures to design a mimic of the viral protein from a different HIV subtype, subtype C, which is responsible for the majority of infections worldwide. Source 6o.
Yes, but the research is so important and every step is a step closer. This disease has gutted whole villages and destroyed the family fabric in many of the places I mentioned. Not to mention the babies born with the disease.
Cow antibodies yield important clues for developing a broadly effective AIDS vaccine. The elicitation of powerful, HIV-blocking antibodies in cows in a matter of weeks -- a process that usually takes years in humans -- has now been described by researchers. The unexpected animal model is providing clues for important questions at a moment when new energy has infused HIV vaccine research. Source 3s.
Big improvements in HIV vaccine production. Research on HIV has led to many promising ideas for vaccines to prevent infection by the AIDS virus, but very few candidate vaccines have been tested in clinical trials. One reason is the technical difficulty of manufacturing vaccines based on the envelope proteins of the virus, according to a vaccine expert who has now developed new methods for the production of HIV vaccines. Source 2u.